<i>FearLess in Neuro-Oncology</i>: Phase I trial targeting fear of cancer recurrence in patients with primary malignant glioma and their caregivers
Findings support continued optimization of <i>FearLess in Neuro-Oncology</i>. Targeted recruitment strategies are needed to reach caregivers, who engaged with and benefitted from the intervention, but were difficult to enroll and retain when not participating as a dyad. Participants reported high perceived benefit and utility of the strategies learned in the intervention.
Authors
- Alexandria Davies (ORCID: https://orcid.org/0000-0001-6978-4788)
- Giuliana Zarrella (ORCID: https://orcid.org/0009-0009-4816-231X)
- Christopher Kleva
- Sarah Braun (ORCID: https://orcid.org/0000-0002-7184-0125)
- Autumn Lanoye (ORCID: https://orcid.org/0000-0003-3705-0880)
- Amber Fox
- Ashlee R. Loughan (ORCID: https://orcid.org/0000-0003-1231-2469)
Institutions
- Virginia Commonwealth University (US)
- Hunter Holmes McGuire VA Medical Center (US)
- Virginia Cancer Institute (US)
- VA Central California Health Care System (US)
- VCU Massey Comprehensive Cancer Center (US)
Publication Details
- Journal
- Neuro-Oncology Practice
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1093/nop/npaf038
- Primary Topic
- Cancer-related cognitive impairment studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00